title: NeuroThera Effectiveness and Safety Trial 3: how do we align corporate and scientific integrity to complete and report pharma-sponsored trials properly?
authors.affiliation: From the Departments of Neurology and Emergency Medicine and Stroke Center, The State University of New York (SUNY) Downstate Medical Center, Brooklyn (S.R.L.); Department of Neurology, The Kings County Hospital Center, Brooklyn, NY (S.R.L.); and The Calgary Stroke Program and Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada (M.D.H.). steven.levine@downstate.edu.
authors.forename: Steven R
authors.initials: SR
authors.lastname: Levine
authors.affiliation: From the Departments of Neurology and Emergency Medicine and Stroke Center, The State University of New York (SUNY) Downstate Medical Center, Brooklyn (S.R.L.); Department of Neurology, The Kings County Hospital Center, Brooklyn, NY (S.R.L.); and The Calgary Stroke Program and Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada (M.D.H.).
authors.forename: Michael D
authors.initials: MD
authors.lastname: Hill
mesh_terms: D023381:Endpoint Determination / Q000592:standards*; D005260:Female; D006801:Humans; D053685:Laser Therapy / Q000379:methods*; D008297:Male; D061214:Patient Safety / Q000592:standards*; D020521:Stroke / Q000628:therapy*
keywords: Editorials; clinical trials phase III; ethics; scientific integrity review